Optimizing Obesity Trials: Integrating Diverse Endpoints to Holistically Assess Safety and Efficacy of GLP-1 Agonists and Beyond Webinar Replay

An estimated 1 billion people are living with obesity worldwide, with adult obesity rates having doubled since 1990 and quadrupled in children and adolescents. Individuals with obesity are at an increased risk of cardiovascular disease, diabetes and certain cancers, among other comorbidities. This increased prevalence combined with the clinical and commercial success of glucagon-like peptide (GLP)-1 agonists for treating both obesity and diabetes has led to a multitude of clinical trials assessing the safety and efficacy of new therapies.

With these studies, researchers are identifying risks and benefits across health disciplines, including cardiovascular, metabolic, mental health, sleep, endocrine and gastrointestinal impacts. For these reasons, it is essential for drug manufacturers to incorporate comprehensive assessments of safety and efficacy to obtain regulatory approval and maximize market opportunities by generating robust data supporting secondary efficacy claims.